Bernstein cuts Amgen PT on uncertainty over obesity drug candidate MariTide

** Bernstein cuts PT on drugmaker Amgen AMGN.O to $350 from $380, citing uncertainty over co's key obesity drug candidate MariTide

** New PT is nearly a 19% upside to stock's last close

** Brokerage says MariTide is a higher-risk-and-high-reward opportunity

** Adds obesity pipeline is advancing but tolerability issues remain

** "We won't yet see the combined impact of the optimized dosing paradigm on weight loss and adverse events at ADA (American Diabetes Association)," says brokerage

** Fifteen of 32 brokerages rate stock "buy" or higher, 14 "hold", and 3 "sell" or lower; median PT is $324 - data compiled by LSEG

** AMGN stock up 12.9% YTD, as of last close; it fell 9.5% in 2024